Clinical Trial Update: Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cetuximab plus avelumab or avelumab alone in unresectable, locally advanced or metastatic squamous cell anal carcinoma that progressed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Anal Carcinoma

Drugs mentioned

• Avelumab (avelumab)
• Cetuximab (cetuximab)

Snippet

Sponsor: Gruppo Oncologico del Nord-Ovest | Conditions: Squamous Cell Anal Carcinoma | Phase 2 | Status: UNKNOWN